- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03143634
The Modular Protocol for Mental Health (MPMH) (MPMH)
The Modular Protocol for Mental Health (MPMH): A Pilot Randomised Clinical Trial of a Transdiagnostic Psychological Treatment for Mood and Anxiety Disorders in Adults
Currently, our best psychological treatments for anxiety and mood disorders only focus on individual diagnoses. So, there are separate treatments for Panic Disorder, or Depressive Disorder, or Social Anxiety, etc. These 'diagnosis-specific' treatments work well for people whose problems fit neatly into a single diagnosis. However, they work far less well for people with complex problems involving multiple diagnoses, and 50% of patients fail to respond well to these existing treatments.
The purpose of this study is to test a new psychological treatment for anxiety and mood problems (the Modular Protocol for Mental Health [MPMH]). Instead of focusing on any single diagnosis, MPMH combines the best treatment techniques into 10 modules to target problems common across all of the different mood and anxiety diagnoses (e.g., intense emotions, negative thinking, upsetting memories, distressing habits). MPMH should therefore be a better treatment for the large numbers of individuals whose problems do not fit neatly into a single diagnosis and for whom any treatments targeting a single diagnosis would leave significant difficulties unaddressed.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Cambridge, United Kingdom, CB2 7EF
- MRC Cognition and Brain Sciences Unit
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with a primary diagnosis of a unipolar mood, anxiety, stress or obsessive-compulsive disorder with at least one additional comorbid diagnosis according to the DSM-5. The criteria for diagnosis will be based on the Structured Clinical Interview for the DSM (SCID) which assesses disorders according to DSM-5 diagnostic criteria.
- To be eligible participants will also need to score >10 on either the Patient Health Questionnaire (PHQ-9) or Generalised Anxiety Disorder -7 item scale, GAD-7 (see Study Measures above).
Exclusion Criteria:
- Current/past psychosis or bipolar disorder
- Current full diagnosis of substance use disorder
- Organic brain damage
- Complex trauma history or recurrent self-injury requiring specialist services (as deemed by the NHS Clinical Care team)
- Current suicidality that warrants immediate clinical attention and constitutes a current risk of harm to the individual.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: The Modular Protocol for Mental Health
The Modular Protocol for Mental Health (Psychological Therapy) will last up to 18 regular weekly face-to-face sessions. Treatment follows a standard structured treatment session as per Cognitive Behavioural Therapy. The MPMH Treatment Manual was written by clinical psychologists. The selection and ordering of the modules for treatment will be delivered and determined by the Trial Clinical Psychologist in collaboration with the service-user. The treatment modules include: M1. Getting Acquainted M2. Understanding Emotions M3. Managing and Tolerating Emotions M4. Behavioural activation M5. Tackling Avoidance M6. Tackling Unhelpful Thoughts M7. Tackling Unhelpful Habits M8. Overcoming Repetitive Thinking M9. Managing Upsetting Memories and Images M10. Relapse Prevention and Future Orientation |
This intervention is based on evidence-based cognitive-behavioural approaches to psychological disorders and offers a flexible approach to treatment delivery that targets the maladaptive processes common to mood and anxiety disorders.
|
Placebo Comparator: Treatment-as-usual
For Treatment-as-usual (Psychological Therapy), clinicians will be asked to provide whatever treatment they deem appropriate, including psychological services, medication and referral to other services.
TAU will be delivered by high-intensity therapists or clinical psychologists.
|
This intervention will consist of psychological therapies delivered by high-intensity therapists or clinical psychologists.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Depression symptoms
Time Frame: Baseline (within two weeks of first treatment session), within one week of the final treatment session, three-months following final treatment session
|
Patient Health Questionnaire - 9-item version (PHQ-9; Kroenke & Spitzer, 2002)
|
Baseline (within two weeks of first treatment session), within one week of the final treatment session, three-months following final treatment session
|
Change in Anxiety symptoms
Time Frame: Baseline (within two weeks of first treatment session), within one week of the final treatment session, three-months following final treatment session
|
General Anxiety Disorder Questionnaire - 7-item version (GAD-7; Spitzer, Kroenke, Williams, & Lowe, 2006)
|
Baseline (within two weeks of first treatment session), within one week of the final treatment session, three-months following final treatment session
|
Change in Level of disability and functional impairment
Time Frame: Baseline (within two weeks of first treatment session), within one week of the final treatment session, three-months following final treatment session
|
Work and Social Adjustment Scale (WSAS; Mundt, J.C. et al., 2002)
|
Baseline (within two weeks of first treatment session), within one week of the final treatment session, three-months following final treatment session
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in symptoms of social phobia, agoraphobia and specific phobia
Time Frame: Baseline (within two weeks of first treatment session), within one week of the final treatment session, three-months following final treatment session
|
IAPT Phobia Scales (Department of Health/IAPT, 2011).
This measure will only be completed by participants with symptoms of social phobia, agoraphobia or specific phobia.
|
Baseline (within two weeks of first treatment session), within one week of the final treatment session, three-months following final treatment session
|
Change in symptoms of social anxiety
Time Frame: Baseline (within two weeks of first treatment session), within one week of the final treatment session, three-months following final treatment session
|
The Social Phobia Inventory (SPIN; Connor, Davidson, Churchill, Sherwood, Foa, & Weisler, 2000).
This measure will only be completed by participants with symptoms of social anxiety.
|
Baseline (within two weeks of first treatment session), within one week of the final treatment session, three-months following final treatment session
|
Change in symptoms of generalised anxiety
Time Frame: Baseline (within two weeks of first treatment session), within one week of the final treatment session, three-months following final treatment session
|
The Penn State Worry Questionnaire (PSWQ; Meyer, Miller, Metzger, & Borkovec, 1990).
This measure will only be completed by participants with symptoms of generalised anxiety disorder.
|
Baseline (within two weeks of first treatment session), within one week of the final treatment session, three-months following final treatment session
|
Change in symptoms of obsessive-compulsive disorder
Time Frame: Baseline (within two weeks of first treatment session), within one week of the final treatment session, three-months following final treatment session
|
The Obsessive-Compulsive Inventory (OCI; Foa, Kozak, Salkovskis, Coles, & Amir, 1998).
This measure will only be completed by participants with symptoms of obsessive-compulsive disorder.
|
Baseline (within two weeks of first treatment session), within one week of the final treatment session, three-months following final treatment session
|
Change in symptoms of post-traumatic stress disorder
Time Frame: Baseline (within two weeks of first treatment session), within one week of the final treatment session, three-months following final treatment session
|
The Revised Impact of Event Scale (IES-R; Weiss, 2007).
This measure will only be completed by participants with symptoms of PTSD.
|
Baseline (within two weeks of first treatment session), within one week of the final treatment session, three-months following final treatment session
|
Change in symptoms of agoraphobia
Time Frame: Baseline (within two weeks of first treatment session), within one week of the final treatment session, three-months following final treatment session
|
The Agoraphobia-Mobility Inventory (MI; Chambless, Caputo, Jasin, Gracely, & Williams, 1985).
This measure will only be completed by participants with symptoms of agoraphobia.
|
Baseline (within two weeks of first treatment session), within one week of the final treatment session, three-months following final treatment session
|
Change in symptoms of specific phobias
Time Frame: Baseline (within two weeks of first treatment session), within one week of the final treatment session, three-months following final treatment session
|
The Fear Questionnaire (FQ; Marks & Mathews, 1979).
This measure will only be completed by participants with symptoms of specific phobia.
|
Baseline (within two weeks of first treatment session), within one week of the final treatment session, three-months following final treatment session
|
Change in symptoms of panic disorder
Time Frame: Baseline (within two weeks of first treatment session), within one week of the final treatment session, three-months following final treatment session
|
The Panic Disorder Severity Scale - self report version (PDSS-SR; Shear, Brown, Barlow, Money, Sholomskas, Woods, Gorman, & Papp, 1997).
This measure will only be completed by participants with symptoms of panic disorder.
|
Baseline (within two weeks of first treatment session), within one week of the final treatment session, three-months following final treatment session
|
Change in symptoms of illness anxiety
Time Frame: Baseline (within two weeks of first treatment session), within one week of the final treatment session, three-months following final treatment session
|
The Health Anxiety Inventory - short version (SHAI; Salkovskis, Rimes, Warwick, & Clark, 2002).
This measure will only be completed by participants with symptoms of illness anxiety.
|
Baseline (within two weeks of first treatment session), within one week of the final treatment session, three-months following final treatment session
|
Change in level of disability and functional impairment
Time Frame: Baseline (within two weeks of first treatment session), within one week of the final treatment session, three-months following final treatment session
|
Sheehan Disability Scale (SDS; Sheehan, 1983)
|
Baseline (within two weeks of first treatment session), within one week of the final treatment session, three-months following final treatment session
|
Change in expectancy about treatment outcome, as well as the credibility of the treatment
Time Frame: Baseline (within two weeks of first treatment session), within one week of the final treatment session, three-months following final treatment session
|
The Treatment Credibility / Expectancy Questionnaire (CEQ; Devilly & Borkovec, 2000)
|
Baseline (within two weeks of first treatment session), within one week of the final treatment session, three-months following final treatment session
|
Change in ability to contextualize negative events within a wider frame of reference
Time Frame: Baseline (within two weeks of first treatment session), within one week of the final treatment session, three-months following final treatment session
|
Cognitive Emotion Regulation Questionnaire (CERQ; Garnefski, Kraaij & Spinhoven, 2000)
|
Baseline (within two weeks of first treatment session), within one week of the final treatment session, three-months following final treatment session
|
Change in disengagement from and acceptance of troublesome mental content, rumination
Time Frame: Baseline (within two weeks of first treatment session), within one week of the final treatment session, three-months following final treatment session
|
Experiences Questionnaire (EQ; Fresco et al., 2007)
|
Baseline (within two weeks of first treatment session), within one week of the final treatment session, three-months following final treatment session
|
Intensity with which participants experience 36 different emotions on a typical day
Time Frame: Baseline (within two weeks of first treatment session), within one week of the final treatment session, three-months following final treatment session
|
Differential Emotions Scale (DES; Izard, 1993)
|
Baseline (within two weeks of first treatment session), within one week of the final treatment session, three-months following final treatment session
|
Change in personality functioning on four subscales: Identity, Self-Direction, Empathy, and Intimacy
Time Frame: Baseline (within two weeks of first treatment session), within one week of the final treatment session, three-months following final treatment session
|
Levels of Personality Functioning Scale (LPFS; Morey et al., 2017)
|
Baseline (within two weeks of first treatment session), within one week of the final treatment session, three-months following final treatment session
|
Change in use of NHS services, other mental health services or activities, help at home, and time off work/lost income
Time Frame: Baseline (within two weeks of first treatment session), within one week of the final treatment session, three-months following final treatment session
|
Healthlines Resource Use Questionnaire (Salisbury, O'Cathain, Edwards, Thomas, Gaunt, Hollinghurst, et al., 2016)
|
Baseline (within two weeks of first treatment session), within one week of the final treatment session, three-months following final treatment session
|
Change in quality of life assessment of health and wellbeing, daily functioning, and general life satisfaction across multiple domains
Time Frame: Baseline (within two weeks of first treatment session), within one week of the final treatment session, three-months following final treatment session
|
World Health Organisation (WHO) Quality of Life Inventory (WHOQOL; World Health Organisation, 1998)
|
Baseline (within two weeks of first treatment session), within one week of the final treatment session, three-months following final treatment session
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in measure of memory specificity
Time Frame: Baseline (within two weeks of first treatment session), within one week of the final treatment session
|
Autobiographical Memory Test (Williams & Broadbent, 1986).
|
Baseline (within two weeks of first treatment session), within one week of the final treatment session
|
Change in cognitive flexibility for emotional information
Time Frame: Baseline (within two weeks of first treatment session), within one week of the final treatment session
|
Affective Card Sorting Task (Barcelo, 2003; Deveney & Deldin, 2006)
|
Baseline (within two weeks of first treatment session), within one week of the final treatment session
|
Change in immediate recall and working memory for neutral information
Time Frame: Baseline (within two weeks of first treatment session), within one week of the final treatment session
|
Digit Span Task (Wechsler, 2008)
|
Baseline (within two weeks of first treatment session), within one week of the final treatment session
|
Change in brief measure of premorbid intelligence
Time Frame: Baseline (within two weeks of first treatment session), within one week of the final treatment session
|
National Adult Reading Test (Nelson & Wilson, 1991)
|
Baseline (within two weeks of first treatment session), within one week of the final treatment session
|
Change in emotional structure (awareness and differentiation)
Time Frame: Baseline (within two weeks of first treatment session), within one week of the final treatment session
|
Levels of Emotional Awareness Scale (Lane et al., 1990)
|
Baseline (within two weeks of first treatment session), within one week of the final treatment session
|
Change in potential neurobiomarkers that may account for risk of disorders and/or predict treatment response (optional component of participation)
Time Frame: Baseline (within two weeks of first treatment session), within one week of the final treatment session
|
Functional connectivity during resting state MRI
|
Baseline (within two weeks of first treatment session), within one week of the final treatment session
|
Change in levels of rumination
Time Frame: Within one-week pre-delivery of relevant treatment module; within one-week post-delivery of relevant treatment module (varied time-frame)
|
Ruminative Responses Scale of the Response Styles Questionnaire (RRS; Treynor, Gonzalez, Nolen-Hoeksema, 2003)
|
Within one-week pre-delivery of relevant treatment module; within one-week post-delivery of relevant treatment module (varied time-frame)
|
Change in ability to tolerate distress
Time Frame: Within one-week pre-delivery of relevant treatment module; within one-week post-delivery of relevant treatment module (varied time-frame)
|
Distress Tolerance Scale (DTS; Simons & Gaher, 2005)
|
Within one-week pre-delivery of relevant treatment module; within one-week post-delivery of relevant treatment module (varied time-frame)
|
Change in ability to label, perceive, and regulate emotions
Time Frame: Within one-week pre-delivery of relevant treatment module; within one-week post-delivery of relevant treatment module (varied time-frame)
|
Difficulties with Emotion Regulation Scale (DERS; Gratz & Roemer, 2004)
|
Within one-week pre-delivery of relevant treatment module; within one-week post-delivery of relevant treatment module (varied time-frame)
|
Change in negative beliefs, thoughts and assumptions
Time Frame: Within one-week pre-delivery of relevant treatment module; within one-week post-delivery of relevant treatment module (varied time-frame)
|
Dysfunctional Attitudes Scale (DAS; Weissman, 1979)
|
Within one-week pre-delivery of relevant treatment module; within one-week post-delivery of relevant treatment module (varied time-frame)
|
Change in mindful awareness
Time Frame: Within one-week pre-delivery of relevant treatment module; within one-week post-delivery of relevant treatment module (varied time-frame)
|
Kentucky Inventory of Mindfulness Skills (KIMS; Baer, Smith, & Allen, 2004)
|
Within one-week pre-delivery of relevant treatment module; within one-week post-delivery of relevant treatment module (varied time-frame)
|
Change in fear of physical anxiety sensations
Time Frame: Within one-week pre-delivery of relevant treatment module; within one-week post-delivery of relevant treatment module (varied time-frame)
|
Anxiety Sensitivity Index (ASI; Reiss, Peterson, Gursky, & McNally 1986)
|
Within one-week pre-delivery of relevant treatment module; within one-week post-delivery of relevant treatment module (varied time-frame)
|
Change in trauma-related beliefs and maladaptive appraisals of intrusive symptoms
Time Frame: Within one-week pre-delivery of relevant treatment module; within one-week post-delivery of relevant treatment module (varied time-frame)
|
Posttraumatic cognitions inventory - short version (PTCI; Foa, Ehlers, Clark, Tolin, Orsillo, 1999)
|
Within one-week pre-delivery of relevant treatment module; within one-week post-delivery of relevant treatment module (varied time-frame)
|
Change in implementation of cognitive therapy skills
Time Frame: Within one-week pre-delivery of relevant treatment module; within one-week post-delivery of relevant treatment module (varied time-frame)
|
Skills of Cognitive Therapy (SoCT; Jarrett, 2010)
|
Within one-week pre-delivery of relevant treatment module; within one-week post-delivery of relevant treatment module (varied time-frame)
|
Change in avoidance of internal experiences including thoughts, feelings, physical sensations.
Time Frame: Within one-week pre-delivery of relevant treatment module; within one-week post-delivery of relevant treatment module (varied time-frame)
|
The Multidimensional Experiential Avoidance Questionnaire (Gamez, Chmielewski, Kotov, Ruggero, & Watson, 2011)
|
Within one-week pre-delivery of relevant treatment module; within one-week post-delivery of relevant treatment module (varied time-frame)
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Tim Dalgleish, PhD, Medical Research Council Cognition and Brain Sciences Unit
Publications and helpful links
General Publications
- Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006 May 22;166(10):1092-7. doi: 10.1001/archinte.166.10.1092.
- Development of the World Health Organization WHOQOL-BREF quality of life assessment. The WHOQOL Group. Psychol Med. 1998 May;28(3):551-8. doi: 10.1017/s0033291798006667.
- Devilly GJ, Borkovec TD. Psychometric properties of the credibility/expectancy questionnaire. J Behav Ther Exp Psychiatry. 2000 Jun;31(2):73-86. doi: 10.1016/s0005-7916(00)00012-4.
- Mundt JC, Marks IM, Shear MK, Greist JH. The Work and Social Adjustment Scale: a simple measure of impairment in functioning. Br J Psychiatry. 2002 May;180:461-4. doi: 10.1192/bjp.180.5.461.
- Reiss S, Peterson RA, Gursky DM, McNally RJ. Anxiety sensitivity, anxiety frequency and the prediction of fearfulness. Behav Res Ther. 1986;24(1):1-8. doi: 10.1016/0005-7967(86)90143-9. No abstract available.
- Baer RA, Smith GT, Allen KB. Assessment of mindfulness by self-report: the Kentucky inventory of mindfulness skills. Assessment. 2004 Sep;11(3):191-206. doi: 10.1177/1073191104268029.
- Meyer TJ, Miller ML, Metzger RL, Borkovec TD. Development and validation of the Penn State Worry Questionnaire. Behav Res Ther. 1990;28(6):487-95. doi: 10.1016/0005-7967(90)90135-6.
- Connor KM, Davidson JR, Churchill LE, Sherwood A, Foa E, Weisler RH. Psychometric properties of the Social Phobia Inventory (SPIN). New self-rating scale. Br J Psychiatry. 2000 Apr;176:379-86. doi: 10.1192/bjp.176.4.379.
- Gamez W, Chmielewski M, Kotov R, Ruggero C, Watson D. Development of a measure of experiential avoidance: the Multidimensional Experiential Avoidance Questionnaire. Psychol Assess. 2011 Sep;23(3):692-713. doi: 10.1037/a0023242.
- Salkovskis PM, Rimes KA, Warwick HM, Clark DM. The Health Anxiety Inventory: development and validation of scales for the measurement of health anxiety and hypochondriasis. Psychol Med. 2002 Jul;32(5):843-53. doi: 10.1017/s0033291702005822.
- Shear MK, Brown TA, Barlow DH, Money R, Sholomskas DE, Woods SW, Gorman JM, Papp LA. Multicenter collaborative panic disorder severity scale. Am J Psychiatry. 1997 Nov;154(11):1571-5. doi: 10.1176/ajp.154.11.1571.
- Chambless DL, Caputo GC, Jasin SE, Gracely EJ, Williams C. The Mobility Inventory for Agoraphobia. Behav Res Ther. 1985;23(1):35-44. doi: 10.1016/0005-7967(85)90140-8. No abstract available.
- Fresco DM, Moore MT, van Dulmen MH, Segal ZV, Ma SH, Teasdale JD, Williams JM. Initial psychometric properties of the experiences questionnaire: validation of a self-report measure of decentering. Behav Ther. 2007 Sep;38(3):234-46. doi: 10.1016/j.beth.2006.08.003. Epub 2007 Apr 24.
- Marks IM, Mathews AM. Brief standard self-rating for phobic patients. Behav Res Ther. 1979;17(3):263-7. doi: 10.1016/0005-7967(79)90041-x. No abstract available.
- Wechsler, D. (2008). Wechsler Adult Intelligence Scale-Fourth Edition. San Antonio, TX: Pearson.
- First MB, Williams JBW, Karg RS, Spitzer RL: Structured Clinical Interview for DSM-5-Research Version (SCID-5 for DSM-5, Research Version; SCID-5-RV). Arlington, VA, American Psychiatric Association, 2015
- Newby JM, McKinnon A, Kuyken W, Gilbody S, Dalgleish T. Systematic review and meta-analysis of transdiagnostic psychological treatments for anxiety and depressive disorders in adulthood. Clin Psychol Rev. 2015 Aug;40:91-110. doi: 10.1016/j.cpr.2015.06.002. Epub 2015 Jun 6.
- Kroenke, K.; Spitzer, R.L.The PHQ-9: A new depression diagnostic and severity measure. Psychiatric Annals, Vol 32(9), Sep 2002, 509-515. http://dx.doi.org/10.3928/0048-5713-20020901-06
- IAPT/Department of Health, The IAPT data handbook version 2.0.1. 2011: Published to Department of Health Website, in electronic PDF format only
- Foa, E.B., Kozak, M.J., Salkovskis, P.M., Coles, M.E., and Amir, N. (1998). The validation of a new obsessive-compulsive disorder scale: The Obsessive-Compulsive Inventory. Psychological Assessment, 10(3), 206-214.
- Weiss, D.S., The Impact of Event Scale: Revised, in Cross-cultural assessment of psychological trauma and PTSD, J.P. Wilson and C.S. Tang, Editors. 2007, Springer: New York. p. 219-238.
- Sheehan, D.V., The Anxiety Disease. 1983, New York: Charles Scribner and Sons.
- Garnefski N, Rieffe C, Jellesma F, Terwogt MM, Kraaij V. Cognitive emotion regulation strategies and emotional problems in 9 - 11-year-old children: the development of an instrument. Eur Child Adolesc Psychiatry. 2007 Feb;16(1):1-9. doi: 10.1007/s00787-006-0562-3. Epub 2006 Jun 21.
- Izard CE, Libero DZ, Putnam P, Haynes OM. Stability of emotion experiences and their relations to traits of personality. J Pers Soc Psychol. 1993 May;64(5):847-60. doi: 10.1037//0022-3514.64.5.847.
- Morey LC. Development and initial evaluation of a self-report form of the DSM-5 Level of Personality Functioning Scale. Psychol Assess. 2017 Oct;29(10):1302-1308. doi: 10.1037/pas0000450. Epub 2017 Feb 27.
- Salisbury C, O'Cathain A, Edwards L, Thomas C, Gaunt D, Hollinghurst S, Nicholl J, Large S, Yardley L, Lewis G, Foster A, Garner K, Horspool K, Man MS, Rogers A, Pope C, Dixon P, Montgomery AA. Effectiveness of an integrated telehealth service for patients with depression: a pragmatic randomised controlled trial of a complex intervention. Lancet Psychiatry. 2016 Jun;3(6):515-25. doi: 10.1016/S2215-0366(16)00083-3. Epub 2016 Apr 27.
- Treynor, W., R. Gonzalez, and S. Nolen-Hoeksema, Rumination Reconsidered: A Psychometric Analysis. Cognitive Therapy and Research 2003. 27(3): p. 247-259.
- Simons, J.S. and R.M. Gaher, The Distress Tolerance Scale: Development and Validation of a Self-Report Measure. Motivation and Emotion, 2005. 29(2): p. 83-102.
- Gratz, K.L. & Roemer, L. Journal of Psychopathology and Behavioral Assessment (2004) 26: 41. doi:10.1023/B:JOBA.0000007455.08539.94
- Weissman, A.N., The Dysfunctional Attitude Scale: A Validation Study. 1979, University of Pennsylvania.
- Foa, E.B., Ehlers, A., Clark, D.M., Tolin, D.F., Orsillo, S.M., The Posttraumatic Cognitions Inventory (PTCI): Development and validation. Psychological Assessment, 1999. 11(3): p. 303-314.
- Jarrett RB, Vittengl JR, Clark LA, Thase ME. Skills of Cognitive Therapy (SoCT): a new measure of patients' comprehension and use. Psychol Assess. 2011 Sep;23(3):578-86. doi: 10.1037/a0022485.
- Williams JM, Broadbent K. Autobiographical memory in suicide attempters. J Abnorm Psychol. 1986 May;95(2):144-9. doi: 10.1037//0021-843x.95.2.144. No abstract available.
- Deveney CM, Deldin PJ. A preliminary investigation of cognitive flexibility for emotional information in major depressive disorder and non-psychiatric controls. Emotion. 2006 Aug;6(3):429-437. doi: 10.1037/1528-3542.6.3.429.
- Barcelo F. The Madrid card sorting test (MCST): a task switching paradigm to study executive attention with event-related potentials. Brain Res Brain Res Protoc. 2003 Mar;11(1):27-37. doi: 10.1016/s1385-299x(03)00013-8.
- Nelson HE, Wilson J (1991) National Adult Reading Test (NART), NFER-Nelson, Windsor, UK.
- Lane RD, Quinlan DM, Schwartz GE, Walker PA, Zeitlin SB. The Levels of Emotional Awareness Scale: a cognitive-developmental measure of emotion. J Pers Assess. 1990 Fall;55(1-2):124-34. doi: 10.1080/00223891.1990.9674052.
- Black M, Hitchcock C, Bevan A, O Leary C, Clarke J, Elliott R, Watson P, LaFortune L, Rae S, Gilbody S, Kuyken W, Johnston D, Newby JM, Dalgleish T. The HARMONIC trial: study protocol for a randomised controlled feasibility trial of Shaping Healthy Minds-a modular transdiagnostic intervention for mood, stressor-related and anxiety disorders in adults. BMJ Open. 2018 Aug 5;8(8):e024546. doi: 10.1136/bmjopen-2018-024546.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Pathologic Processes
- Mood Disorders
- Trauma and Stressor Related Disorders
- Phobic Disorders
- Stress Disorders, Traumatic
- Depressive Disorder
- Disease
- Obsessive-Compulsive Disorder
- Anxiety Disorders
- Stress Disorders, Post-Traumatic
- Depressive Disorder, Major
- Phobia, Social
- Panic Disorder
- Agoraphobia
Other Study ID Numbers
- MP:MH RfPB PB-PG-0214-33072
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obsessive-Compulsive Disorder
-
Anne Katrine PagsbergCopenhagen Trial Unit, Center for Clinical Intervention Research; Danish Research...Active, not recruitingObsessive-Compulsive Disorder in Children | Obsessive-Compulsive Disorder in AdolescenceDenmark
-
Baylor College of MedicineRecruitingObsessive-Compulsive Disorder | Cognitive Behavioral Therapy | Obsessive-Compulsive Disorder in Children | Obsessive-Compulsive Disorder in AdolescenceUnited States
-
Chaim HuijserLevvelRecruitingObsessive-Compulsive Disorder | Anxiety Disorders and Symptoms | Obsessive-Compulsive Disorder in Children | Obsessive-Compulsive Disorder in AdolescenceNetherlands
-
Stanford UniversityCompletedObsessive Compulsive DisorderUnited States
-
NYU Langone HealthCompletedObsessive Compulsive DisorderUnited States
-
Massachusetts General HospitalActive, not recruitingObsessive Compulsive DisorderUnited States
-
Boston University Charles River CampusCompletedObsessive Compulsive DisorderUnited States
-
Butler HospitalNational Institute of Mental Health (NIMH)CompletedObsessive Compulsive DisorderUnited States
-
Karolinska InstitutetCompletedObsessive Compulsive DisorderSweden
-
Roseli ShavittCompleted
Clinical Trials on The Modular Protocol for Mental Health
-
University of Maryland, BaltimoreUniversity of UtahCompletedMental Health Wellness 1United States
-
Columbia UniversityNational Institute of Mental Health (NIMH)SuspendedDepressive Disorder | Bipolar Disorder | Mental Disorders, Severe | Schizophrenia and Related DisordersUnited States
-
Johns Hopkins UniversityNational Institute of Mental Health (NIMH)CompletedDepression | Anxiety | Parent-Child Relations | Attention Deficit Hyperactivity Disorder | Substance Use | Oppositional Defiant DisorderIran, Islamic Republic of
-
University of California, Los AngelesUniversity of California, Davis; California Department of Health ServicesCompletedDigital Mental Health Resources (Website) for Coping With Stress and InformationUnited States
-
Medical University of LublinCompletedOveractive Bladder | Urinary Incontinence | Stress Urinary Incontinence | Urge IncontinencePoland
-
Dartmouth-Hitchcock Medical CenterNational Institute of Mental Health (NIMH)Enrolling by invitationHealth Anxiety | Illness Anxiety Disorder | Somatic Symptom DisorderUnited States
-
University of PennsylvaniaNeuroFlowRecruitingBehavioral Economics | Gifts, Financial | PointUnited States
-
Mayo ClinicRecruitingPrimary Progressive Aphasia | Apraxia of Speech | Primary Progressive Nonfluent Aphasia | Non-fluent AphasiaUnited States
-
Ludwig-Maximilians - University of MunichProf. OTTO Beisheim Stiftung (Germany)CompletedDepressive Disorder | Depression in AdolescenceGermany
-
University of TromsoUniversity of Bergen; Norwegian University of Science and Technology; UiT The... and other collaboratorsRecruitingDepression, Anxiety | School Phobia | Absence | Truancy; SocializedNorway